After Long Decline, Industry Spending On CME Programs Rises Again
This article was originally published in The Gray Sheet
Drug and device companies increased funding for continuing medical education programs by 2.4 percent in 2014 to $675.9 million; support had declined steadily since peaking in 2007.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.